ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity

Zhang, Yuankun; Song, Qingxiao; Cassady, Kaniel; Lee, Michael; Tang, Haidong; Zheng, Moqian; Wang, Bixin; Schones, Dustin E.; Fu, Yang-Xin; Riggs, Arthur D.; Martin, Paul J.; Feng, Ru*; Zeng, Defu*南方医科大学; 清华大学
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA2023-4-18DOI: 10.1073/pnas.2205085120
4被引6阅读
引用收藏
分享

摘要

PD-L1 has two receptors: PD-1 and CD80. Previous reports assumed that PD-L1 and CD80 interacted in trans, but recent reports showed that only cis PD-L1/CD80 interactions existed, and prevention of cis PD-L1/CD80 interactions on antigen-presenting cells (APCs) reduced antitumor immunity via augmenting PD-L1/PD-1 and CD80/ CTLA4 interactions between T and APCs. Here, using tumor-bearing mice capable of cis and trans or trans only PD-L1/CD80 interactions, we show that trans PD-L1/CD80 interactions do exist between tumor and T cells, and the effects of trans PD-L1/CD80 interactions require tumor cell expression of MHC-I and T cell expression of CD28. The blockade of PD-L1/CD80 interactions in mice with both cis and trans interactions or with only trans interactions augments antitumor immunity by expanding IFN-& gamma;-producing CD8+ T cells and IFN-& gamma;-dependent NOS2-expressing tumor-associated macrophages. Our studies indicate that although cis and trans PD-L1/CD80 interactions may have opposite effects on antitumor immunity, the net effect of blocking PD-L1/CD80 interactions in vivo augments CD8+ T cell-mediated antitumor immunity.

学科与关键词

关键词
PD-L1CD80PD-L1 interaction with CD80CD8+T cellstumor immunity
相关
加载中…
  • Blockade of PD-L1 interaction with CD80 in trans augments anti-tumor immunity by increasing NOS2 in tumor-associated macrophages.
    Zhang, Yuankun; Song, Qingxiao; Lee, Michael; Tang, Haidong; Cassady, Kaniel; Fu, Yang-Xin; Schones, Dustin E.; Riggs, Arthur; Feng, Ru; Zeng, DefuAnnual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia, PA, 2021-04-10 To 2021.
  • The primordial differentiation of tumor-specific memory CD8+T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes
    Huang, Qizhao; Wu, Xia; Wang, Zhiming; Chen, Xiangyu; Wang, Lisha; Lu, Yijun; Xiong, Dan; Liu, Qiao; Tian, Yuhan; Lin, Huayu; Guo, Junyi; Wen, Shuqiong; Dong, Wei; Yang, Xiaofan; Yuan, Yuchen; Yue, Zhengliang; Lei, Shun; Wu, Qing; Ran, Ling; Xie, Luoyingzi; Wang, Yifei; Gao, Leiqiong; Tian, Qin; Zhou, Xinyuan; Sun, Beicheng*; Xu, Lifan*; Tang, Zhonghui*; Ye, Lilin*Cell, 2022, 185(22): 4049-+.被引 61
  • The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
    Tang, Qing; Chen, Yun; Li, Xiaojuan; Long, Shunqin; Shi, Yao; Yu, Yaya; Wu, Wanyin*; Han, Ling*; Wang, Sumei*Frontiers in Immunology, 2022, 13: 964442.被引 57
查看全部 →

发表信息

论文状态
公开发表
期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
发表日期
2023-04-18
卷期
第 120 卷, 第 16 期
页码
e2205085120
DOI
10.1073/pnas.2205085120
语言
ENGLISH
成果收录
SCIE
资助标注
NIH [43H12, PD-L1-/- C57BL/6]; Riggs Transplantation Immunology Fund [R01 CA228465]

作者

  • Z

    Zhang, Yuankun (第一作者)

    southern med univ

  • S

    Song, Qingxiao

    fujian med univ

查看全部 13 位作者收起作者
  • C

    Cassady, Kaniel

  • L

    Lee, Michael

  • T

    Tang, Haidong

    tsinghua univ

  • Z

    Zheng, Moqian

  • W

    Wang, Bixin

    fujian med univ

  • S

    Schones, Dustin E.

  • F

    Fu, Yang-Xin

    tsinghua univ

  • R

    Riggs, Arthur D.

  • M

    Martin, Paul J.

  • F

    Feng, Ru (通讯)

    southern med univ

  • Z

    Zeng, Defu (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417